HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
about
Impact of polysomy 17 on HER2 testing of invasive breast cancer patientsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItQuantification of HER family receptors in breast cancerImpact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationGene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.HER2/neu testing in primary colorectal carcinoma.Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.Updated UK Recommendations for HER2 assessment in breast cancer.Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast CarcinomasHER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.HER2 status determination: analyzing the problems to find the solutions.Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancerSignificant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsComparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detectionAlteration status and prognostic value of MET in head and neck squamous cell carcinoma.HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival.Pathological examination of breast cancer biomarkers: current status in Japan.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue.Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.The assessment of HER2 status in breast cancer: the past, the present, and the future.Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.
P2860
Q24619955-BD2F5B81-C25C-4011-B6BF-323F77F3B38CQ26752780-94A7F2AD-D2F6-4426-A281-F200A7020440Q27015506-14082546-52DA-44C1-A8EA-EFED8FB6576BQ30996906-9D26D7A5-CCD8-4A70-A651-708E04E32184Q33741544-A662C319-5FDC-4F16-A1B4-0A1DF25B5247Q33862786-B5B8EAFF-21D4-47F1-AF37-E21857C26B7AQ34010867-B6DCBC47-0BB9-40E1-AB47-138D575F1783Q34084063-F5E19ECD-05F3-4E3D-9989-20C9116B0125Q34458036-098CAD0C-0F6C-48FF-ADED-0F3A045AF656Q34499615-BC3BFE77-2E70-4B31-A75F-F7779D0B51A9Q35000497-BFDB2771-A196-4D6F-8E0E-01F108BF29BEQ35048548-4D25EE2C-EC7E-4BD5-9B9A-5667FEC3B6DBQ35633666-0C62CEA6-4472-404C-8C6D-638544B3244DQ35687706-520D9437-58E7-494E-996D-0F0493B2EF72Q36087126-9A9D89DD-FC7C-4420-8521-D48BF7DA8D7DQ36151207-6218FA19-5829-4A5B-8192-F184BD6345E6Q36246729-6793755A-68B5-4323-8EE0-20129A5B447EQ36559818-4E826D5C-E68E-4E9D-8E24-26EC3B5AC803Q36801203-D66746E1-B402-47B7-AF13-2C8D1EA7B0F1Q37075632-0BC4A3BA-ABAB-4942-8CFE-3E2E3784955BQ37246183-6CE4AC78-D718-43D4-98E9-108ACE23E403Q37514050-30C62933-5FF1-40FB-9AEC-2B77A4621526Q37582166-33FDCBC6-DE50-4FF8-BEF9-E1C9D1F1FD67Q37746218-73A61F40-F689-4379-8B00-331D04EE57B3Q38252702-CF75C50A-69DE-4778-88E3-8BEBBF18E852Q38314355-891D508A-35F4-46BC-915E-4054D723CF8FQ38326102-184D0F4D-2B48-4190-9847-46733A762434Q38549208-B2F68D4B-874D-4C73-A009-DC52CA5BD380Q38612634-596868E4-8E8D-4D03-8C94-81E0A39A4ED0Q38656185-D9D07207-88E6-42BF-87CF-50A676287726Q38723467-83CE7392-4974-46A4-B894-81C0DF2FEBE4Q38802932-5534E31C-6394-43B2-AA85-3563D9059265Q39022194-B3ACF28D-A228-40C1-B115-608E1A2A43B1Q39187437-DD684927-B5CD-4594-B380-90AEE0969967Q39292642-D81086A3-2728-47D1-B9C8-CC6EA96DDD31Q39983856-1A221553-CB7B-4CF8-94D8-D58655EF47F6Q40076929-BF0BCC7A-789A-4001-AA38-E8E11916C09AQ40338226-3D8247A3-3572-43DD-B8AA-3BECEAB9CD17Q40453735-E6BDB5BC-9AEE-4916-B689-C101ED20AB45Q40490703-DC0DA6BE-30D4-4E1D-BBCF-25760BE464C3
P2860
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@ast
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@en
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@nl
type
label
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@ast
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@en
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@nl
prefLabel
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@ast
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@en
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@nl
P2093
P2860
P50
P3181
P1433
P1476
HER2 in situ hybridization in ...... y 17 and genetic heterogeneity
@en
P2093
Josef Rüschoff
Michael Bilous
Renata A Coudry
Robert Y Osamura
Wedad M Hanna
P2860
P2888
P3181
P356
10.1038/MODPATHOL.2013.103
P407
P577
2014-01-01T00:00:00Z
P5875
P6179
1017540202